Hanrahan, Aphrothiti J.
Chen, Ziyu http://orcid.org/0000-0002-1198-1516
Rosen, Neal
Solit, David B. http://orcid.org/0000-0002-6614-802X
Article History
Accepted: 12 December 2023
First Online: 26 January 2024
Competing interests
: N.R. is on the scientific advisory board (SAB) and owns equity in Beigene, MapKure, Ribon and Zai Labs; is also on the SAB of AstraZeneca, Chugai, Concarlo and Ikena; is a past SAB member of Araxes, Kura, Novartis and Takeda (formerly Millennium); has equity in Effector, Fortress and Kura; is a consultant to Array/Pfizer, Boeringher Ingelheim, Eli Lilly, RevMed, Tarveda and Verustem; and receives research funding from Array/Pfizer, AstraZeneca, Boerhinger Ingelheim and Revmed. D.B.S. has served as a consultant and/or SAB member for BridgeBio, Elsie Biotherapeutics, Fog Pharma, Fore Therapeutics, Function Oncology, Lilly/Loxo Oncology, PaigeAI, Pfizer, Scorpion Therapeutics and Vividion Therapeutics. The other authors declare no competing interests.